CD4 and Alzheimer disease: MT administration reduced inflammatory process in the skin, which was suggested by decreased SCORAD in AD patients [97] and histological skin assessment in NC/Nga atopic-like mice, decrease in serum IgE, and decline in secretion of IL-4 and INF-γ from activated CD4+ cells [98,99].